Adding Merck to my Dividend Portfolio
News out of the imuno-oncology sector of the biotech world has hit stocks in my portfolios such as Incyte (INCY) and Nektar Therapeutics (NKTR) hard. But, I'd argue that it has left Keytruda and its owner Merck (MRK) in a measurably stronger position in the market for...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Leveraging near-term Incyte catalysts by adding call options to Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto...
Buying call Nektar options at $90 for August 17, 2018 expiration in my Volatility Portfolio
When I started my rebalancing of my Volatility Portfolio on February 20, I thought I would add the slightly in the money Nektar Therapeutics (NKTR) calls at $80 with an expiration of August 17, 2018 at a closing price of $18.50. But the underlying stock has moved up...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year's gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid and...
Time to buy Incyte on the biotech dip
Maybe you didn't even know there was a biotech dip. If all you've been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you're likely to respond "What dip?" Nektar...
Nektar soars–again–on oncology drug data
Shares of Nektar Therapeutics (NKTR) are up another 16% this morning to $37.89 as of noon New York time on data presented this weekend at the annual meeting of the Society for Immunotherapy of Cancer from an early trial of Nektar's NKTR-214. The data looked at the...
Some signs the bottom is in for Incyte
This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The...
Lessons from my bad trade in INCY call options in my Volatility Portfolio
Wow. That sure didn’t work the way I intended. Back on May 23 I added the July 21 $140 calls on Incyte (INCY) to my Volatility Portfolio. Those calls traded at $7.10 that day. As I wrote in my post that day, to make money on these options, I’d need to get a move of $4 or so to move the share price above $140 and to move the options into the money. My logic at the time was pretty simple.
